Literature DB >> 17338934

Combination therapy and new types of agents for pulmonary arterial hypertension.

Dermot S O'Callaghan1, Dermot O'Callaghan, Sean P Gaine.   

Abstract

This review assesses the available evidence supporting the use of drug combinations for the management of the various forms of pulmonary arterial hypertension (PAH). Ongoing and forthcoming randomized trials evaluating this strategy are also highlighted. Furthermore, new types of agents to treat PAH in the future are explored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338934     DOI: 10.1016/j.ccm.2006.11.011

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  12 in total

1.  Pulmonary arterial hypertension.

Authors:  Sheng Chin Wu; Sergio Caravita; Elisabetta Lisi; Simona Pierini; Viola Dadone; Sarah E Todd; Francesco Gentile; Maria Beatrice Secchi
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

Review 2.  An update on medical therapy for pulmonary arterial hypertension.

Authors:  Yan Wu; Dermot S O'Callaghan; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 3.  Treatment of pulmonary arterial hypertension with targeted therapies.

Authors:  Dermot S O'Callaghan; Laurent Savale; David Montani; Xavier Jaïs; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Nat Rev Cardiol       Date:  2011-07-19       Impact factor: 32.419

Review 4.  Is a regenerative approach viable for the treatment of COPD?

Authors:  Matthew Hind; Malcolm Maden
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

5.  ERG evaluation of daily, high-dose sildenafil usage.

Authors:  Christopher I Zoumalan; Roham T Zamanian; Ramona L Doyle; Michael F Marmor
Journal:  Doc Ophthalmol       Date:  2008-09-26       Impact factor: 2.379

6.  Pulmonary hypertension: diagnosis and management.

Authors:  Michael D McGoon; Garvan C Kane
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

7.  Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.

Authors:  Patricia N Sidharta; Paul L M van Giersbergen; Michael Wolzt; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

8.  Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.

Authors:  Nancy R Porhownik; Hassan Al-Sharif; Zoheir Bshouty
Journal:  Can Respir J       Date:  2008 Nov-Dec       Impact factor: 2.409

9.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

10.  Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.

Authors:  Mai Kimura; Yuichi Tamura; Makoto Takei; Tsunehisa Yamamoto; Tomohiko Ono; Jun Fujita; Masaharu Kataoka; Masataka Kuwana; Toru Satoh; Keiichi Fukuda
Journal:  BMC Pulm Med       Date:  2015-05-14       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.